- Home
- BTT vs CSTL Comparison
BTT vs CSTL Comparison
Compare BTT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTT | CSTL |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BTT | CSTL |
|---|---|---|
| Price | $22.75 | $39.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 151.1K | ★ 356.4K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $343,530,000.00 |
| Revenue This Year | N/A | $2.55 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $18.90 | $14.59 |
| 52 Week High | $21.86 | $44.28 |
Technical Indicators
Market Signals| Indicator | BTT | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 46.13 |
| Support Level | $22.48 | $39.74 |
| Resistance Level | $22.72 | $44.28 |
| Average True Range (ATR) | 0.15 | 1.76 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 65.00 | 12.49 |
Price Performance
Historical ComparisonAbout BTT BlackRock Municipal 2030 Target Term Trust
Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.